We believe this site might serve you best:

United States

United States

Choose language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

ApoLive-Glo™ Multiplex Assay

G6410

Measure Viability and Apoptosis in the Same Sample Well

  • Accurately determine mechanism of cell death in less time, with less sample
  • Easy to implement using a simple sequential 'add-mix-measure' protocol
  • Adaptable to meet various throughput needs

Size

Catalog number selected: G6410

$ 515.00 Your price: Log In

Add to Helix Add to Helix
ApoLive-Glo™ Multiplex Assay
10ml
$ 515.00
Your price: Log In
Change Configuration

Two Technologies Combined in One Effective Assay

The ApoLive-Glo™ Multiplex Assay measures both the number of viable cells as a marker of cytotoxicity and caspase activation as a marker of apoptosis within a single assay well to determine the mechanism of cell death. The first part of the assay measures the activity of a protease marker of cell viability. The live-cell protease activity is restricted to intact viable cells and is measured using a fluorogenic, cell-permeant, peptide substrate (glycyl-phenylalanyl-amino fluorocoumarin; GF-AFC). The substrate enters intact cells, where it is cleaved by the live-cell protease activity to generate a fluorescent signal proportional to the number of living cells. This live-cell protease becomes inactive upon loss of cell membrane integrity and leakage into the surrounding culture medium.

The second part of the assay uses the Caspase-Glo® Assay technology to detect caspase activation, a key biomarker of apoptosis. The Caspase-Glo® Assay provides a luminogenic caspase-3/7 substrate, which contains the tetrapeptide sequence DEVD, in a reagent optimized for caspase activity, luciferase activity and cell lysis. Adding the Caspase-Glo® 3/7 Reagent in an 'add-mix-measure' format results in cell lysis, followed by caspase cleavage of the substrate and generation of a 'glow-type' luminescent signal produced by luciferase. Luminescence is proportional to the amount of caspase activity present.

Predictive Measures of Viability and Apoptosis in the Same Sample Well

8141MA-W
Necrosis Results

Ionomycin treatment of Jurkat cells for 6 hours results in dose-dependent decrease in viability and increase in cytotoxicity with no caspase-3/7 activation, consistent with primary necrosis.

8140MA-W
Apoptosis Results

Staurosporine treatment of Jurkat cells for 6 hours results in a dose-dependent decrease in viability and increase in cytotoxicity with an increase in caspase-3/7 activity consistent with apoptosis.

Specifications

You are viewing: G6410 Change Configuration

What's in the box?

Item Part # Size

GF-AFC Substrate

G608A 1 × 10μl

Assay Buffer

G610A 1 × 10ml

Caspase-Glo® 3/7 Buffer

G810A 1 × 10ml

Caspase-Glo® 3/7 Substrate

G811A 1 × 1 bottle

SDS

Choose language:

Certificate of Analysis

Search for Specific Certificate:

View more results
View more results
Loading…

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

 

Patents and Disclaimers

U.S. Pat. Nos. 7,148,030, 7,384,758, 7,666,987 and 8,071,328 and other patents and patents pending.

U.S. Pat. Nos. 7,416,854, 7,553,632 and other patents pending.

U.S. Pat. Nos. 6,602,677, 7,241,584, 8,030,017 and 8,822,170 and other patents and patents pending.

Specifications

You are viewing: G6411 Change Configuration

What's in the box?

Item Part # Size

GF-AFC Substrate

G608B 1 × 50μl

Assay Buffer

G610A 2 × 10ml

Caspase-Glo® 3/7 Buffer

G810A 5 × 10ml

Caspase-Glo® 3/7 Substrate

G811A 5 × 1 bottle

SDS

Choose language:

Certificate of Analysis

Search for Specific Certificate:

View more results
View more results
Loading…

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

 

Patents and Disclaimers

U.S. Pat. Nos. 7,148,030, 7,384,758, 7,666,987 and 8,071,328 and other patents and patents pending.

U.S. Pat. Nos. 7,416,854, 7,553,632 and other patents pending.

U.S. Pat. Nos. 6,602,677, 7,241,584, 8,030,017 and 8,822,170 and other patents and patents pending.

Choose your country

Americas

Brazil
Canada
United States

Pacific Asia

Australia
India
Japan
Korea, Republic of
Singapore

Europe

Austria
Belgium
Denmark
Estonia
Finland
France
Germany
Iceland
Italy
Luxembourg
Netherlands
Norway
Poland
Spain
Sweden
Switzerland
United Kingdom